CV vs GEHC
CV: CapsoVision commercializes AI-powered capsule endoscopy systems with panoramic imaging for small bowel and emerging colon diagnostics, targeting gastroenterologists globally. GEHC: GE HealthCare is a leading medical technology company providing advanced diagnostic imaging, patient monitoring, and AI-driven clinical software to help clinicians manage complex diseases.
Side-by-side fundamentals
| Metric | CV | GEHC | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.91 | $61.41 | |
| Market cap as of 2026-07-23 | $353M | $27.9B | |
| P/E as of 2026-07-23 | n/a | 14.63 | |
| PEG as of 2026-07-23 | n/a | 2.18 | |
| Net margin as of 2026-07-23 | -198.9% | +9.1% | GEHC higher |
| Gross margin as of 2026-07-23 | +51.7% | +39.1% | CV higher |
| Operating margin as of 2026-07-23 | -200.7% | +12.6% | GEHC higher |
| ROE as of 2026-07-23 | -184.2% | +18.8% | GEHC higher |
| ROA as of 2026-07-23 | -136.0% | +5.3% | GEHC higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.95 | CV lower |
| Revenue growth (YoY) as of 2026-07-23 | +0.3% | +6.0% | GEHC higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +4.0% | |
| Dividend yield as of 2026-07-23 | n/a | +0.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 3 | |
| Beta as of 2026-07-23 | -1.83 | 0.84 | |
| 1-year return as of 2026-07-22 close | +57.8% | -16.3% | CV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.